Antoine C G Egberts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8023113/publications.pdf

Version: 2024-02-01

473 papers

20,167 citations

75 h-index 19690 117 g-index

490 all docs

490 docs citations

490 times ranked 19235 citing authors

#	Article	IF	CITATIONS
1	The association between patient satisfaction with information and adherence to oral anticancer agents. Journal of Oncology Pharmacy Practice, 2023, 29, 637-645.	0.5	O
2	Identifying adverse drug reactions from freeâ€ŧext electronic hospital health record notes. British Journal of Clinical Pharmacology, 2022, 88, 1235-1245.	1.1	11
3	The effect of a decision support system on the incidence of prescription errors in a PICU. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 330-344.	0.7	10
4	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	0.6	12
5	Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting. European Geriatric Medicine, 2022, , 1.	1.2	5
6	The association between skeletal muscle measures and chemotherapyâ€induced toxicity in nonâ€small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1554-1564.	2.9	18
7	Clarity and applicability of adverse drug reaction-related monitoring instructions in clinical practice guidelines for children and adolescents treated with antipsychotic drugs: a review of six clinical practice guidelines. BMJ Open, 2022, 12, e058940.	0.8	1
8	Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase. European Neuropsychopharmacology, 2022, 58, 30-38.	0.3	3
9	Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity. Drugs and Aging, 2022, 39, 59-73.	1.3	15
10	Patients Retransitioning from Biosimilar TNF \hat{l}_{\pm} Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs, 2022, 36, 27-39.	2.2	3
11	Contextualized Drug–Drug Interaction Management Improves Clinical Utility Compared With Basic Drug–Drug Interaction Management in Hospitalized Patients. Clinical Pharmacology and Therapeutics, 2022, 112, 382-390.	2.3	3
12	Systemic glucocorticoid use during ICU admission and symptoms of posttraumatic stress disorder in intensive care unit survivors. Intensive Care Medicine, 2022, , $1.$	3.9	0
13	Nature and timing of post-approval manufacturing changes of tumour necrosis factor $\hat{l}\pm$ inhibitor products: A 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences, 2022, 175, 106227.	1.9	1
14	Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12725.	1.0	9
15	Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNFâ€Î± Inhibitors. Clinical Pharmacology and Therapeutics, 2021, 110, 123-131.	2.3	4
16	Clinical Decision Support Systemâ€Assisted Pharmacy Intervention Reduces Feeding Tube–Related Medication Errors in Hospitalized Patients: A Focus on Medication Suitable for Feedingâ€Tube Administration. Journal of Parenteral and Enteral Nutrition, 2021, 45, 625-632.	1.3	8
17	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. Schizophrenia Bulletin, 2021, 47, 672-681.	2.3	4
18	Nature and frequency of prescription modifications in community pharmacies: A nationwide study in the Netherlands. British Journal of Clinical Pharmacology, 2021, 87, 1455-1465.	1.1	3

#	Article	IF	CITATIONS
19	Influence of allopurinol on thiopurine associated toxicity: A retrospective populationâ€based cohort study. British Journal of Clinical Pharmacology, 2021, 87, 2333-2340.	1.1	4
20	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals, 2021, 69, 30-37.	0.5	2
21	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals, 2021, 14, 189.	1.7	4
22	Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics. Frontiers in Psychiatry, 2021, 12, 640377.	1.3	1
23	Waste-minimising measures to achieve sustainable supply and use of medication. Sustainable Chemistry and Pharmacy, 2021, 20, 100400.	1.6	31
24	Switching TNFα inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 2021, 9, e00843.	1.1	3
25	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. Clinical Pharmacokinetics, 2021, 60, 1395-1406.	1.6	19
26	Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners. Journal of Child and Adolescent Psychopharmacology, 2021, , .	0.7	1
27	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. BioDrugs, 2021, 35, 765-772.	2.2	0
28	The effect of the anticholinergic burden on duration and severity of delirium in older hipâ€surgery patients with and without haloperidol prophylaxis: A post hoc analysis. Brain and Behavior, 2021, 11, e2404.	1.0	4
29	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. Journal of Personalized Medicine, 2021, 11, 1233.	1.1	5
30	Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatric Research, 2020, 87, 689-696.	1.1	14
31	Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen. British Journal of Clinical Pharmacology, 2020, 86, 75-84.	1.1	9
32	Clinical ruleâ€guided pharmacists' intervention in hospitalized patients with hypokalaemia: A time series analysis. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 520-529.	0.7	5
33	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. European Journal of Pharmaceutical Sciences, 2020, 154, 105501.	1.9	11
34	Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients?. Clinical Infection in Practice, 2020, 7-8, 100046.	0.2	4
35	Reporting Patterns of Sialorrhea Comparing Users of Clozapine to Users of Other Antipsychotics. Journal of Clinical Psychopharmacology, 2020, 40, 283-286.	0.7	6
36	Association between serum biomarkers CEA and LDH and response in advanced nonâ€small cell lung cancer patients treated with platinumâ€based chemotherapy. Thoracic Cancer, 2020, 11, 1790-1800.	0.8	20

3

#	Article	IF	CITATIONS
37	Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites. Clinical Pharmacology and Therapeutics, 2020, 108, 1098-1106.	2.3	12
38	Evaluation of clarity of the STOPP/START criteria for clinical applicability in prescribing for older people: a quality appraisal study. BMJ Open, 2020, 10, e033721.	0.8	9
39	Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion. European Neuropsychopharmacology, 2020, 36, 244-254.	0.3	25
40	Psychotropic medication use in former ICU patients with mental health problems: A prospective observational follow-up study. Journal of Critical Care, 2020, 59, 112-117.	1.0	2
41	Comparison between coagulation factor VIII quantified with oneâ€stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle. International Journal of Laboratory Hematology, 2020, 42, 819-826.	0.7	2
42	Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study. European Journal of Internal Medicine, 2020, 78, 121-126.	1.0	8
43	Translation from animal to clinical studies, choosing the optimal moment. Pediatric Research, 2020, 88, 836-837.	1.1	1
44	A semiâ€mechanistic model based on glutathione depletion to describe intraâ€individual reduction in busulfan clearance. British Journal of Clinical Pharmacology, 2020, 86, 1499-1509.	1.1	18
45	The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: A case/non-case study using VigiBase. European Neuropsychopharmacology, 2020, 35, 30-38.	0.3	5
46	Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. Neonatology, 2019, 116, 154-162.	0.9	26
47	The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study. BMC Health Services Research, 2019, 19, 717.	0.9	9
48	Associations between personality traits and adequate home storage of drugs in older patients. Psychology, Health and Medicine, 2019, 24, 1255-1266.	1.3	2
49	Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 124-132.	0.7	25
50	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research, 2019, 19, 243.	0.9	17
51	Discontinuation Rates of Antidepressant Use by Dutch Soldiers. Military Medicine, 2019, 184, 868-874.	0.4	2
52	Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia. PLoS ONE, 2019, 14, e0211910.	1.1	17
53	Redispensing of unused HIV post-exposure prophylaxis for medical students. Travel Medicine and Infectious Disease, 2019, 29, 82-83.	1.5	4
54	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. BMJ Open, 2019, 9, e024767.	0.8	22

#	Article	IF	Citations
55	Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis. BMJ Open, 2019, 9, e029148.	0.8	4
56	Pharmacist-Psychiatrist Interventions Triggered by Clinical Decision Support System Improve Monitoring of Patients Using Lithium in a General Hospital. Journal of Clinical Psychopharmacology, 2019, 39, 532-533.	0.7	1
57	Postâ€marketing dosing changes in the label of biologicals. British Journal of Clinical Pharmacology, 2019, 85, 715-721.	1.1	4
58	Compliance with the guidelines for laboratory monitoring of patients treated with lithium: A retrospective followâ€up study among ambulatory patients in the Netherlands. Bipolar Disorders, 2019, 21, 419-427.	1.1	10
59	Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study. Drug Safety, 2019, 42, 887-895.	1.4	23
60	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. Research in Social and Administrative Pharmacy, 2019, 15, 100-105.	1.5	22
61	Severe Cognitive Impairment Associated With a High Free But Therapeutic Total Concentration of Valproic Acid Due to Hypoalbuminemia in an Older Patient With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 265-268.	0.7	6
62	Older Patients' Compliance with Drug Storage Recommendations. Drugs and Aging, 2018, 35, 233-241.	1.3	16
63	The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. Pharmaceutical Research, 2018, 35, 42.	1.7	24
64	Comparison of antibiotic dosing recommendations for neonatal sepsis from established reference sources. International Journal of Clinical Pharmacy, 2018, 40, 436-443.	1.0	13
65	Development of a nomogram for the estimation of longâ€term adherence to clozapine therapy using neutrophil fluorescence. British Journal of Clinical Pharmacology, 2018, 84, 1228-1237.	1.1	6
66	Monitoring of patients treated with lithium for bipolar disorder: an international survey. International Journal of Bipolar Disorders, 2018, 6, 12.	0.8	23
67	Patient and medication factors associated with preventable medication waste and possibilities for redispensing. International Journal of Clinical Pharmacy, 2018, 40, 704-711.	1.0	27
68	Effects of training physicians in electronic prescribing in the outpatient setting on clinical, learning and behavioural outcomes: a cluster randomized trial. British Journal of Clinical Pharmacology, 2018, 84, 1187-1197.	1.1	5
69	Monitoring of Metabolic, Cardiac, and Endocrine Indicators in Youth Treated With Antipsychotics as Reported by Health Care Professionals. Journal of Clinical Psychopharmacology, 2018, 38, 489-493.	0.7	10
70	Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study. Therapeutic Advances in Psychopharmacology, 2018, 8, 213-229.	1.2	4
71	Glucose variability during delirium in diabetic and non-diabetic intensive care unit patients: A prospective cohort study. PLoS ONE, 2018, 13, e0205637.	1.1	12
72	Evaluation of clarity of presentation and applicability of monitoring instructions for patients using lithium in clinical practice guidelines for treatment of bipolar disorder. Bipolar Disorders, 2018, 20, 708-720.	1.1	12

#	Article	IF	CITATIONS
73	Pharmacists' Activities to Reduce Medication Waste: An International Survey. Pharmacy (Basel,) Tj ETQq1 1	0.784314	rgBT /Overlo
74	Nitric Oxide Synthase Inhibition as a Neuroprotective Strategy Following Hypoxic–Ischemic Encephalopathy: Evidence From Animal Studies. Frontiers in Neurology, 2018, 9, 258.	1.1	31
75	Megakaryocyte lineage development is controlled by modulation of protein acetylation. PLoS ONE, 2018, 13, e0196400.	1.1	3
76	Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts. Healthcare (Switzerland), 2018, 6, 23.	1.0	31
77	Diabetes and Glucose Dysregulation and Transition to Delirium in ICU Patients. Critical Care Medicine, 2018, 46, 1444-1449.	0.4	23
78	Prevalence of use of erectile dysfunction medication by Dutch military personnel between 2003 and 2012. International Journal of Impotence Research, 2017, 29, 54-56.	1.0	3
79	Redispensing of medicines unused by patients: a qualitative study among stakeholders. International Journal of Clinical Pharmacy, 2017, 39, 196-204.	1.0	27
80	The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine. Journal of Clinical Psychopharmacology, 2017, 37, 155-161.	0.7	24
81	Hypertensive Crisis During Norepinephrine Syringe Exchange. A & A Case Reports, 2017, 8, 178-181.	0.7	2
82	Paediatric Drug Development and Formulation Designâ€"a European Perspective. AAPS PharmSciTech, 2017, 18, 241-249.	1.5	52
83	Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital. PLoS ONE, 2017, 12, e0174513.	1.1	18
84	Guidance by physicians and pharmacists during antidepressant therapy: patients' needs and suggestions for improvement. BMC Psychiatry, 2017, 17, 388.	1.1	6
85	Prevalence of Psychotropic Medication Use Among Dutch Military Personnel Between 2003 and 2012 and Its Comparison to the Dutch General Population. Military Medicine, 2017, 182, e1584-e1588.	0.4	4
86	The Relation between Psychiatric Diagnoses and Constipation in Hospitalized Patients: A Cross-Sectional Study. Psychiatry Journal, 2016, 2016, 1-4.	0.7	11
87	The effect of exposure misclassification in spontaneous ADR reports on the time to detection of productâ€specific risks for biologicals: a simulation study. Pharmacoepidemiology and Drug Safety, 2016, 25, 297-306.	0.9	8
88	Anti-epileptic drug changes and quality of life in the community. Acta Neurologica Scandinavica, 2016, 133, 421-426.	1.0	3
89	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	2.2	197
90	Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Archives of Disease in Childhood, 2016, 101, 662-669.	1.0	49

#	Article	IF	CITATIONS
91	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology, 2016, 55, 704-709.	0.9	45
92	Dosing errors in preterm neonates due to flow rate variability in multi-infusion syringe pump setups: An in vitro spectrophotometry study. European Journal of Pharmaceutical Sciences, 2016, 93, 56-63.	1.9	11
93	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. Pharmacoepidemiology and Drug Safety, 2016, 25, 88-102.	0.9	23
94	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. Pharmacoepidemiology and Drug Safety, 2016, 25, 21-28.	0.9	14
95	The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiology and Drug Safety, 2016, 25, 5-10.	0.9	20
96	Multiâ€centre, multiâ€database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 2016, 25, 156-165.	0.9	36
97	Patient monitoring: the hidden costs of treatment with antipsychotics. British Journal of Clinical Pharmacology, 2016, 82, 570-572.	1.1	1
98	Movement Disorders in Adults With Intellectual Disability and Behavioral Problems Associated With Use of Antipsychotics. Journal of Clinical Psychopharmacology, 2016, 36, 308-313.	0.7	13
99	Associations Between Personality Traits and Adherence to Antidepressants Assessed Through Self-Report, Electronic Monitoring, and Pharmacy Dispensing Data. Journal of Clinical Psychopharmacology, 2016, 36, 465-471.	0.7	7
100	Structured Medication Review to Improve Pharmacotherapy in People with Intellectual Disability and Behavioural Problems. Journal of Applied Research in Intellectual Disabilities, 2016, 29, 346-355.	1.3	32
101	Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Research in Developmental Disabilities, 2016, 49-50, 13-21.	1.2	47
102	The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study. Drug Safety, 2016, 39, 79-87.	1.4	54
103	MEDUCATE trial: effectiveness of an intensive EDUCATional intervention for IT-mediated MEDication management in the outpatient clinic – study protocol for a cluster randomized controlled trial. Trials, 2015, 16, 223.	0.7	3
104	Drugâ€induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. Clinical Pharmacology and Therapeutics, 2015, 98, 542-550.	2.3	21
105	Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: Overview and applicability in clinical practice. Journal of Psychopharmacology, 2015, 29, 1248-1254.	2.0	17
106	Influence of a strict glucose protocol on serum potassium and glucose concentrations and their association with mortality in intensive care patients. Critical Care, 2015, 19, 270.	2.5	11
107	Antidepressant use in pregnancy: knowledge transfer and translation of research findings. Journal of Evaluation in Clinical Practice, 2015, 21, 579-583.	0.9	2
108	Adherence with Dosing Guideline in Patients with Impaired Renal Function at Hospital Discharge. PLoS ONE, 2015, 10, e0128237.	1.1	30

#	Article	IF	CITATIONS
109	Task analysis of information technologyâ€mediated medication management in outpatient care. British Journal of Clinical Pharmacology, 2015, 80, 415-424.	1.1	11
110	How to use current practice, risk analysis and standards to define hospital-wide policies on the safe use of infusion technology. Biomedizinische Technik, 2015, 60, 381-7.	0.9	3
111	Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiology and Drug Safety, 2015, 24, 276-285.	0.9	23
112	Anticonvulsant Effectiveness and Hemodynamic Safety of Midazolam in Full-Term Infants Treated with Hypothermia. Neonatology, 2015, 107, 150-156.	0.9	32
113	Medication Discontinuation in Patients After Discharge From a Psychiatric Hospital. Annals of Pharmacotherapy, 2015, 49, 1085-1095.	0.9	3
114	Methods of administering oral formulations and child acceptability. International Journal of Pharmaceutics, 2015, 491, 261-267.	2.6	45
115	Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1153-1162.	1.6	11
116	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematology,the, 2015, 2, e194-e203.	2.2	228
117	Risk of Hospitalization for Hypoglycemia inÂOlder Patients with Diabetes Using Antipsychotic Drugs. American Journal of Geriatric Psychiatry, 2015, 23, 1144-1153.	0.6	7
118	Adverse Drug Reactions Reported With Cholinesterase Inhibitors. Annals of Pharmacotherapy, 2015, 49, 1197-1206.	0.9	36
119	Flow variability and its physical causes in infusion technology: a systematic review of in vitro measurement and modeling studies. Biomedizinische Technik, 2015, 60, 277-300.	0.9	33
120	The relation between risk-taking behavior and alcohol use in young adults is different for men and women. Drug and Alcohol Dependence, 2015, 155, 222-227.	1.6	26
121	Traceability of biologicals: present challenges in pharmacovigilance. Expert Opinion on Drug Safety, 2015, 14, 63-72.	1.0	37
122	Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT Project. Current Clinical Pharmacology, 2014, 9, 130-138.	0.2	48
123	Effect of a Transitional Pharmaceutical Care Intervention at Hospital Discharge on Registration of Changes in Medication Regimens in Primary Care. Journal of the American Geriatrics Society, 2014, 62, 565-567.	1.3	3
124	The influence of lithium on calcium homeostasis in older patients in daily clinical practice. International Journal of Geriatric Psychiatry, 2014, 29, 594-601.	1.3	8
125	Combined HTR2C-LEP and HTR2C-LEPR Genotypes as a Determinant for Obesity in Patients Without Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2014, 34, 266-268.	0.7	0
126	Oral Medicines for Children in the European Paediatric Investigation Plans. PLoS ONE, 2014, 9, e98348.	1.1	20

#	Article	IF	Citations
127	Participation of Older People in Preauthorization Trials of Recently Approved Medicines. Journal of the American Geriatrics Society, 2014, 62, 1883-1890.	1.3	38
128	Practical Problems with Medication Use that Older People Experience: A Qualitative Study. Journal of the American Geriatrics Society, 2014, 62, 2339-2344.	1.3	90
129	Variability between nursing homes in prevalence of antipsychotic use in patients with dementia. International Psychogeriatrics, 2014, 26, 363-371.	0.6	37
130	Prospective Validation of a Busulfan Pharmacokinetic Model in Children: Therapeutic Drug Monitoring Remains of Utmost Importance to Optimize Outcomes of HCT. Biology of Blood and Marrow Transplantation, 2014, 20, S248.	2.0	0
131	Medication management capacity in relation to cognition and self-management skills in older people on polypharmacy. Journal of Nutrition, Health and Aging, 2014, 18, 44-49.	1.5	47
132	Association between ADHD drug use and injuries among children and adolescents. European Child and Adolescent Psychiatry, 2014, 23, 95-102.	2.8	35
133	Multiple physicians are not independently associated with inappropriate prescribing: a crossâ€sectional study of geriatric patients. British Journal of Clinical Pharmacology, 2014, 77, 213-215.	1.1	2
134	Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporosis International, 2014, 25, 385-392.	1.3	19
135	Impact of computerized physician order entry (CPOE) on PICU prescribing errors. Intensive Care Medicine, 2014, 40, 458-459.	3.9	6
136	Analysis of Potential Drugâ€Drug Interactions in Medical Intensive Care Unit Patients. Pharmacotherapy, 2014, 34, 213-219.	1.2	65
137	Discontinuation of Somatic Medication During Psychiatric Hospitalization. Annals of Pharmacotherapy, 2014, 48, 1415-1424.	0.9	4
138	Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. European Journal of Clinical Pharmacology, 2014, 70, 849-857.	0.8	135
139	Completeness of patient records in community pharmacies post-discharge after in-patient medication reconciliation: a before-after study. International Journal of Clinical Pharmacy, 2014, 36, 807-814.	1.0	12
140	Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study. Diabetes Care, 2014, 37, 2218-2224.	4.3	126
141	Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe. Clinical Pharmacology and Therapeutics, 2014, 96, 723-731.	2.3	27
142	QT Interval Prolongation in Users of Selective Serotonin Reuptake Inhibitors in an Elderly Surgical Population. Journal of Clinical Psychiatry, 2014, 75, 15-21.	1.1	21
143	The association between CYP2D6 genotype and switching antipsychotic medication to clozapine. European Journal of Clinical Pharmacology, 2013, 69, 1927-1932.	0.8	3
144	The association between prescription change frequency, chronic disease score and hospital admissions: a case control study. BMC Pharmacology & Empty Toxicology, 2013, 14, 39.	1.0	8

#	Article	IF	Citations
145	Information for Adequate Prescribing to Older Patients. Drugs and Aging, 2013, 30, 255-262.	1.3	19
146	Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases. Drug Safety, 2013, 36, 617-625.	1.4	64
147	Signs and Symptoms Indicative of Potential Adverse Drug Reactions in Homecare Patients. Journal of the American Medical Directors Association, 2013, 14, 920-925.	1.2	20
148	Renal function assessment in older adults. British Journal of Clinical Pharmacology, 2013, 76, n/a-n/a.	1.1	39
149	Fluorescence of neutrophil granulocytes as a biomarker for clozapine use. European Neuropsychopharmacology, 2013, 23, 1408-1413.	0.3	6
150	Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. Pharmaceutical Statistics, 2013, 12, 366-374.	0.7	10
151	Prevalence of hyponatremia on geriatric wards compared to other settings over four decades: A systematic review. Ageing Research Reviews, 2013, 12, 165-173.	5.0	66
152	Treatment of epilepsy in daily clinical practice: have outcomes improved over the past 10Âyears?. Journal of Neurology, 2013, 260, 2736-2743.	1.8	10
153	Prognostic factors for medically intractable epilepsy: A systematic review. Epilepsy Research, 2013, 106, 301-310.	0.8	52
154	Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability. Research in Developmental Disabilities, 2013, 34, 3159-3167.	1.2	30
155	Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: A cross-sectional study. Maturitas, 2013, 76, 357-363.	1.0	44
156	Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. European Journal of Clinical Pharmacology, 2013, 69, 1701-1707.	0.8	42
157	Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 305-313.	2.0	99
158	Prevalence of Medication Use for Somatic Disease in Institutionalized Psychiatric Patients. Pharmacopsychiatry, 2013, 46, 274-280.	1.7	7
159	Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2013, 98, F341-F345.	1.4	39
160	The Effect of a Computerized Prescribing and Calculating System on Hypo- and Hyperglycemias and on Prescribing Time Efficiency in Neonatal Intensive Care Patients. Journal of Parenteral and Enteral Nutrition, 2013, 37, 85-91.	1.3	21
161	Acceptability of different oral formulations in infants and preschool children. Archives of Disease in Childhood, 2013, 98, 725-731.	1.0	107
162	Age as a Determinant of Instability of Serum Lithium Concentrations. Therapeutic Drug Monitoring, 2013, 35, 643-648.	1.0	8

#	Article	IF	CITATIONS
163	Genetic Variation and the Risk of Haloperidol-Related Parkinsonism in Elderly Patients. Journal of Clinical Psychopharmacology, 2013, 33, 405-410.	0.7	12
164	Systems that prevent unwanted represcription of drugs withdrawn because of adverse drug events: a systematic review. Therapeutic Advances in Drug Safety, 2013, 4, 73-90.	1.0	23
165	Effect of a Discharge Medication Intervention on the Incidence and Nature of Medication Discrepancies in Older Adults. Journal of the American Geriatrics Society, 2013, 61, 456-458.	1.3	5
166	Preventing hospital admissions by reviewing medication (PHARM) in primary care: an open controlled study in an elderly population. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 379-387.	0.7	38
167	Feasibility of point-of-care creatinine testing in community pharmacy to monitor drug therapy in ambulatory elderly patients. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 416-422.	0.7	21
168	The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice (CME). Transfusion, 2013, 53, 1930-1939.	0.8	14
169	Occurrence and determinants of poor response to shortâ€term preâ€operative erythropoietin treatment. Acta Anaesthesiologica Scandinavica, 2013, 57, 350-357.	0.7	5
170	Taxol ^{\hat{A}^{\otimes}} -induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor ^{\hat{A}^{\otimes}} EL. Nanomedicine, 2013, 8, 1127-1135.	1.7	22
171	Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 235-240.	1.4	70
172	Clinical pharmacy interventions in paediatric electronic prescriptions. Archives of Disease in Childhood, 2013, 98, 222-227.	1.0	25
173	Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. Pharmacogenomics Journal, 2013, 13, 318-324.	0.9	7
174	The Effect of Psychotropic Medications on the Occurrence of Constipation in Hospitalized Psychiatric Patients. Journal of Clinical Psychopharmacology, 2013, 33, 587-590.	0.7	4
175	The Views of Healthcare Professionals, Drug Developers and Regulators on Information about Older People Needed for Rational Drug Prescription. PLoS ONE, 2013, 8, e72060.	1.1	7
176	Selective Serotonin Reuptake Inhibitors and Intraoperative Blood Pressure. American Journal of Hypertension, 2012, 25, 223-228.	1.0	8
177	Risk of acute coronary syndrome in elderly users of antipsychotic drugs: a nested case-control study. Heart, 2012, 98, 1166-1171.	1.2	9
178	Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults. Therapeutic Drug Monitoring, 2012, 34, 574-583.	1.0	48
179	Parkinsonism in Elderly Users of Haloperidol. Journal of Clinical Psychopharmacology, 2012, 32, 688-693.	0.7	12
180	Contribution of Renal Impairment to Potentially Preventable Medication-Related Hospital Admissions. Annals of Pharmacotherapy, 2012, 46, 625-633.	0.9	34

#	Article	IF	CITATIONS
181	Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics, 2012, 13, 571-578.	0.6	14
182	Instructions on laboratory monitoring in 200 drug labels. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1351-8.	1.4	13
183	Information comparison of the effects of drugs on laboratory tests in drug labels and Young's book. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1765-8.	1.4	3
184	Association Between HTR2C Polymorphisms and Obesity in Patients Without Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2012, 32, 715-740.	0.7	2
185	Valproic Acid Treatment Is Associated With Altered Leukocyte Subset Development. Journal of Clinical Psychopharmacology, 2012, 32, 832-834.	0.7	12
186	Reasons for and Time to Discontinuation of Rimonabant Therapy. Drug Safety, 2012, 35, 1147-1158.	1.4	10
187	Pharmacokinetics and Clinical Efficacy of Phenobarbital in Asphyxiated Newborns Treated with Hypothermia. Clinical Pharmacokinetics, 2012, 51, 671-679.	1.6	70
188	Serum Potassium Influencing Interacting Drugs: Risk-Modifying Strategies Also Needed at Discontinuation. Annals of Pharmacotherapy, 2012, 46, 176-182.	0.9	6
189	Quality of Life of Elderly Patients With Antipsychotic-Induced Parkinsonism: A Cross-Sectional Study. Journal of the American Medical Directors Association, 2012, 13, 82.e1-82.e5.	1.2	10
190	Effect of Medication Reconciliation on Medication Costs After Hospital Discharge in Relation to Hospital Pharmacy Labor Costs. Annals of Pharmacotherapy, 2012, 46, 329-338.	0.9	22
191	Differences in Lithium Use Patterns in the Netherlands: Comparing Middle-Aged and Older Patients in a Database Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 193-200.	3.0	7
192	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. Clinical Pharmacokinetics, 2012, 51, 331-345.	1.6	115
193	Use of Rivastigmine or Galantamine and Risk of Adverse Cardiac Events: A Database Study from the Netherlands. American Journal of Geriatric Pharmacotherapy, 2012, 10, 373-380.	3.0	15
194	An Electronic System to Document Reasons for Medication Discontinuation and to Flag Unwanted Represcriptions in Geriatric Patients. Drugs and Aging, 2012, 29, 957-962.	1.3	8
195	Rituximabâ€induced thrombocytopenia: a cohort study. European Journal of Haematology, 2012, 89, 256-266.	1.1	31
196	Dopamine agonists and ischemic complications in Parkinson's disease: a nested case–control study. European Journal of Clinical Pharmacology, 2012, 68, 83-88.	0.8	13
197	Antidepressive Treatment With Monoamine Oxidase Inhibitors and the Occurrence of Intraoperative Hemodynamic Events. Journal of Clinical Psychiatry, 2012, 73, 1103-1109.	1.1	33
198	Polymorphisms of the <i>LEP</i> , <i>LEPR</i> and <i>HTR2C</i> gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics, 2011, 12, 919-923.	0.6	36

#	Article	IF	Citations
199	Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study. Value in Health, 2011, 14, 34-40.	0.1	87
200	The Authors' Reply. Drug Safety, 2011, 34, 354-355.	1.4	0
201	Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures. Clinical Pharmacokinetics, 2011, 50, 461-469.	1.6	36
202	Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic Chemotherapy. Drug Safety, 2011, 34, 1151-1160.	1.4	54
203	The availability and ageâ€appropriateness of medicines authorized for children in the Netherlands. British Journal of Clinical Pharmacology, 2011, 72, 465-473.	1.1	44
204	Structured History Taking of Medication Use Reveals latrogenic Harm Due to Discrepancies in Medication Histories in Hospital and Pharmacy Records. Journal of the American Geriatrics Society, 2011, 59, 1976-1977.	1.3	43
205	Use of Serotonergic Drugs and the Risk of Bleeding. Clinical Pharmacology and Therapeutics, 2011, 89, 89-96.	2.3	47
206	Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems. Journal of Intellectual Disability Research, 2011, 55, 650-664.	1.2	24
207	The decision to continue or discontinue treatment: Experiences and beliefs of users of selective serotonin-reuptake inhibitors in the initial monthsâ€"A qualitative study. Research in Social and Administrative Pharmacy, 2011, 7, 134-150.	1.5	44
208	Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics, 2011, 12, 1213-1227.	0.6	17
209	Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study. Osteoporosis International, 2011, 22, 2197-2204.	1.3	29
210	Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology, 2011, 216, 111-120.	1.5	67
211	Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs. European Journal of Clinical Pharmacology, 2011, 67, 933-940.	0.8	17
212	Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study. BMC Health Services Research, 2011, 11, 4.	0.9	28
213	High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. Arthritis and Rheumatism, 2011, 63, 2007-2013.	6.7	126
214	Discriminative value of platelet size indices for the identification of the mechanism of chemotherapy-induced thrombocytopenia. Biomarkers, 2011, 16, 51-57.	0.9	7
215	Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics, 2011, 12, 1485-1492.	0.6	11
216	Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase. Diabetes Care, 2011, 34, 369-374.	4.3	112

#	Article	IF	CITATIONS
217	Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients. Journal of Clinical Psychopharmacology, 2010, 30, 526-530.	0.7	35
218	Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication. Psychiatric Genetics, 2010, 20, 311-316.	0.6	21
219	Combined HTR2C-LEP Genotype as a Determinant of Obesity in Patients Using Antipsychotic Medication. Journal of Clinical Psychopharmacology, 2010, 30, 702-705.	0.7	16
220	The Association Between Serotonin 2C Receptor Polymorphisms and Weight Gain and Eating Behavior in Patients Using Mirtazapine. Journal of Clinical Psychopharmacology, 2010, 30, 207-209.	0.7	5
221	Reasons for Discontinuation of Medication During Hospitalization and Documentation Thereof: A Descriptive Study of 400 Geriatric and Internal Medicine Patients. Archives of Internal Medicine, 2010, 170, 1081.	4.3	12
222	298 Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients. Pediatric Research, 2010, 68, 153-153.	1.1	0
223	479 Model-Based Lidocaine Dosing Regimen for Seizure Control in Preterm and Term Neonates. Pediatric Research, 2010, 68, 244-245.	1.1	O
224	Use of Serotonergic Antidepressants and Bleeding Risk in Orthopedic Patients. Anesthesiology, 2010, 112, 631-636.	1.3	67
225	Patients' concerns about and problems experienced with discontinuation of antidepressants. International Journal of Pharmacy Practice, 2010, 15, 291-293.	0.3	7
226	Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology, 2010, 212, 379-391.	1.5	93
227	Quantifying antibiotic use in paediatrics: a proposal for neonatal DDDs. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1301-1303.	1.3	34
228	Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45Âyears in the Netherlands. ADHD Attention Deficit and Hyperactivity Disorders, 2010, 2, 213-220.	1.7	35
229	The effect of the COACH program (Continuity Of Appropriate pharmacotherapy, patient Counselling) Tj ETQq1 1 internal medicine patients. BMC Health Services Research, 2010, 10, 39.	0.784314 0.9	rgBT /Overl 28
230	Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: A systematic literature review. Clinical Therapeutics, 2010, 32, 924-938.	1.1	29
231	Seasonal patterns of initiating antidepressant therapy in general practice in the Netherlands during 2002–2007. Journal of Affective Disorders, 2010, 122, 208-212.	2.0	21
232	Antibiotic weightâ€watching: slimming down on antibiotic use in a NICU. Acta Paediatrica, International Journal of Paediatrics, 2010, 99, 1900-1902.	0.7	11
233	Comparison of potential risk factors for medication errors with and without patient harm. Pharmacoepidemiology and Drug Safety, 2010, 19, 825-833.	0.9	13
234	Frequency and nature of drug–drug interactions in a Dutch university hospital. British Journal of Clinical Pharmacology, 2010, 70, 618-618.	1.1	37

#	Article	IF	CITATIONS
235	Medication discontinuity errors in the perioperative period. Acta Anaesthesiologica Scandinavica, 2010, 54, 1185-1191.	0.7	11
236	The Association Between Patient-Reported Drug Taking and Gaps and Overlaps in Antidepressant Drug Dispensing. Annals of Pharmacotherapy, 2010, 44, 1755-1761.	0.9	11
237	Reply to R. Ferraldeschi et al. Journal of Clinical Oncology, 2010, 28, e586-e586.	0.8	0
238	Glycopyrrolate for sialorrhea in Parkinson disease. Neurology, 2010, 74, 1203-1207.	1.5	125
239	Trends in Incidence and Characteristics of Children, Adolescents, and Adults Initiating Immediate- or Extended-Release Methylphenidate or Atomoxetine in The Netherlands During 2001–2006. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 55-61.	0.7	37
240	Variation in antibiotic use in neonatal intensive care units in the Netherlands. Journal of Antimicrobial Chemotherapy, 2010, 65, 1270-1275.	1.3	57
241	Transitions from General Practitioner to Psychiatrist Care (or vice versa) during a First Antidepressant Treatment Episode. Pharmacopsychiatry, 2010, 43, 179-183.	1.7	5
242	Novel insights in pharmacogenetics of drug response in Parkinson's disease. Pharmacogenomics, 2010, 11, 127-129.	0.6	11
243	Trials Assessing Parmacotherapeutic Management of Aggression in Psychiatric Patients: Comparability with Clinical Practice. Pharmacopsychiatry, 2010, 43, 205-209.	1.7	6
244	Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2423-2429.	0.8	150
245	The Relationship Between Study Characteristics and the Prevalence of Medication-Related Hospitalizations. Drug Safety, 2010, 33, 233-244.	1.4	82
246	Antipsychotic-Induced Hyponatraemia. Drug Safety, 2010, 33, 101-114.	1.4	86
247	Effects of Hypothermia on Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics, 2010, 49, 277-294.	1.6	165
248	Recurrence of Adverse Drug Reactions following Inappropriate Re-Prescription. Drug Safety, 2010, 33, 535-538.	1.4	29
249	Hyponatraemia as an Adverse Drug Reaction of Antipsychotic Drugs. Drug Safety, 2010, 33, 569-578.	1.4	51
250	Mapping the Safety Profile of Biologicals. Drug Safety, 2010, 33, 865-878.	1.4	40
251	Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. Journal of Clinical Epidemiology, 2010, 63, 422-427.	2.4	90
252	Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example. Journal of Clinical Epidemiology, 2010, 63, 728-736.	2.4	146

#	Article	IF	CITATIONS
253	Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone, 2010, 47, 604-609.	1.4	84
254	Patients' perceptions and illness severity at start of antidepressant treatment in general practice. International Journal of Pharmacy Practice, 2010, 18, 217-225.	0.3	17
255	Prevalence and Determinants of Thyroid Disorders in Elderly Patients With Affective Disorders: Lithium and Nonlithium Patients. American Journal of Geriatric Psychiatry, 2010, 18, 395-403.	0.6	37
256	The Relationship between Benzodiazepine Use and Traffic Accidents. CNS Drugs, 2010, 24, 639-653.	2.7	141
257	Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands. Drugs and Aging, 2010, 27, 663-675.	1.3	22
258	Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology, 2009, 23, 909-914.	2.0	79
259	The Effect of Computerized Physician Order Entry on Medication Prescription Errors and Clinical Outcome in Pediatric and Intensive Care: A Systematic Review. Pediatrics, 2009, 123, 1184-1190.	1.0	227
260	Documentation Quality in Community Pharmacy: Completeness of Electronic Patient Records After Patients' First Visits. Annals of Pharmacotherapy, 2009, 43, 1787-1794.	0.9	20
261	Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients. Quality and Safety in Health Care, 2009, 18, 22-27.	2.5	71
262	Unexpected Lower Prevalence of Depression in Patients With Diabetes. Epidemiology, 2009, 20, 419-423.	1.2	0
263	Gardarsdottir et al. Respond to "Assessing Treatment Effects With Observational Analyses". American Journal of Epidemiology, 2009, 170, 288-288.	1.6	0
264	Duration of Antidepressant Drug Treatment and Its Influence on Risk of Relapse/Recurrence: Immortal and Neglected Time Bias. American Journal of Epidemiology, 2009, 170, 280-285.	1.6	38
265	Patients' Perceptions of Information Received at the Start of Selective Serotonin-Reuptake Inhibitor Treatment: Implications for Community Pharmacy. Annals of Pharmacotherapy, 2009, 43, 642-649.	0.9	29
266	Compliance with Platelet Count Monitoring Recommendations and Management of Possible Heparin-Induced Thrombocytopenia in Hospitalized Patients Receiving Low-Molecular-Weight Heparin. Annals of Pharmacotherapy, 2009, 43, 1405-1412.	0.9	16
267	Validity and reliability of the Simpsonâ€Angus Scale (SAS) in drug induced parkinsonism in the elderly. International Journal of Geriatric Psychiatry, 2009, 24, 183-189.	1.3	21
268	Reliability of the medication appropriateness index in Dutch residential home. International Journal of Clinical Pharmacy, 2009, 31, 380-386.	1.4	19
269	Antidepressant use before and after initiation of diabetes mellitus treatment. Diabetologia, 2009, 52, 425-432.	2.9	30
270	Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporosis International, 2009, 20, 1499-1506.	1.3	82

#	Article	IF	Citations
271	Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporosis International, 2009, 20, 1705-1713.	1.3	80
272	Reply: long-term retention rate of pramipexole in the treatment of Parkinson's disease. European Journal of Clinical Pharmacology, 2009, 65, 957-957.	0.8	2
273	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. European Journal of Clinical Pharmacology, 2009, 65, 1245-1251.	0.8	27
274	An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. Pharmacoepidemiology and Drug Safety, 2009, 18, 7-15.	0.9	32
275	Cardiovascular and psychiatric risk profile and patterns of use in patients starting antiâ€obesity drugs. Pharmacoepidemiology and Drug Safety, 2009, 18, 631-638.	0.9	9
276	Risk of drugâ€induced photosensitivity: focus on spectroscopic and molecular characteristics. Pharmacoepidemiology and Drug Safety, 2009, 18, 602-609.	0.9	12
277	Frequency and nature of drug–drug interactions in a Dutch university hospital. British Journal of Clinical Pharmacology, 2009, 68, 187-193.	1.1	89
278	Association between lithium serum level, mood state, and patientâ€reported adverse drug reactions during longâ€term lithium treatment: a naturalistic followâ€up study. Bipolar Disorders, 2009, 11, 434-440.	1.1	24
279	Association between antidepressant drug use during pregnancy and child healthcare utilisation. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1568-1577.	1.1	12
280	Treatment Choices and Patterns in Migraine Patients With and Without a Cardiovascular Risk Profile. Cephalalgia, 2009, 29, 322-330.	1.8	8
281	Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 231-241.	2.0	107
282	Platelet Measurements versus Discharge Diagnoses for Identification of Patients with Potential Drug-Induced Thrombocytopenia. Drug Safety, 2009, 32, 69-76.	1.4	10
283	Laboratory Tests in the Clinical Risk Management of Potential Drug-Drug Interactions. Drug Safety, 2009, 32, 1189-1197.	1.4	20
284	Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy. Clinical Pharmacokinetics, 2009, 48, 677-683.	1.6	84
285	Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval. Drug Safety, 2009, 32, 1175-1187.	1.4	46
286	Pharmacist-Based Medication Review Reduces Potential Drug-Related Problems in the Elderly. Drugs and Aging, 2009, 26, 123-133.	1.3	110
287	The Influence that Electronic Prescribing Has on Medication Errors and Preventable Adverse Drug Events: an Interrupted Time-series Study. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 816-825.	2.2	102
288	Medication Safety: Effect of Medication Reconciliation with and Without Patient Counseling on the Number of Pharmaceutical Interventions Among Patients Discharged from the Hospital. Annals of Pharmacotherapy, 2009, 43, 1001-1010.	0.9	92

#	Article	IF	Citations
289	Evaluation of Available Treatment Guidelines for the Management of Lithium Intoxication. Therapeutic Drug Monitoring, 2009, 31, 247-260.	1.0	10
290	Does the Length of the First Antidepressant Treatment Episode Influence Risk and Time to a Second Episode?. Journal of Clinical Psychopharmacology, 2009, 29, 69-72.	0.7	22
291	Polymorphisms of the LEP- and LEPR Gene and Obesity in Patients Using Antipsychotic Medication. Journal of Clinical Psychopharmacology, 2009, 29, 21-25.	0.7	74
292	Influence of Antidepressant Use on Glycemic Control in Patients With Diabetes Mellitus. Journal of Clinical Psychopharmacology, 2009, 29, 405-408.	0.7	7
293	HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 16-20.	0.7	74
294	Initiation of antidepressant therapy: do patients follow the GP's prescription?. British Journal of General Practice, 2009, 59, 81-87.	0.7	100
295	The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. International Psychogeriatrics, 2009, 21, 931.	0.6	28
296	The relationship between drug use and traffic accident severity., 2009,, 135-150.		0
297	The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. European Journal of Clinical Pharmacology, 2008, 64, 531-538.	0.8	85
298	Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. European Journal of Clinical Pharmacology, 2008, 64, 1021-1026.	0.8	11
299	European commission consultation on pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2008, 17, 108-109.	0.9	5
300	The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case–control study. Pharmacoepidemiology and Drug Safety, 2008, 17, 336-344.	0.9	38
301	Reliability of the assessment of preventable adverse drug events in daily clinical practice. Pharmacoepidemiology and Drug Safety, 2008, 17, 645-654.	0.9	37
302	Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiology and Drug Safety, 2008, 17, 577-586.	0.9	30
303	Renal effects of longâ€term lithium therapy in the elderly: a crossâ€sectional study. International Journal of Geriatric Psychiatry, 2008, 23, 685-692.	1.3	37
304	Psychiatric and Cardiovascular Comorbidities in Patients With Diabetes Mellitus Starting Antiobesity Drugs. Obesity, 2008, 16, 2331-2335.	1.5	3
305	Pharmacogenetics: From Bench to Byte. Clinical Pharmacology and Therapeutics, 2008, 83, 781-787.	2.3	229
306	Clinical relevance of patients with epilepsy included in clinical trials. Epilepsia, 2008, 49, 1479-1480.	2.6	19

#	Article	IF	CITATIONS
307	Antipsychotic Drug Use and Risk of Pneumonia in Elderly People. Journal of the American Geriatrics Society, 2008, 56, 661-666.	1.3	174
308	Relationship between polypharmacy and underprescribing. British Journal of Clinical Pharmacology, 2008, 65, 130-133.	1.1	209
309	Serotonin transporter polymorphism and bleeding time during SSRI therapy. British Journal of Clinical Pharmacology, 2008, 65, 761-766.	1.1	23
310	The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30â€∫mg oxazepam. British Journal of Clinical Pharmacology, 2008, 66, 556-560.	1.1	35
311	Prevalence and determinants of pharmacy shopping behaviour. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 17-23.	0.7	106
312	Changes in outpatient lithium treatment in the Netherlands during 1996–2005. Journal of Affective Disorders, 2008, 111, 94-99.	2.0	20
313	The relation between the blood benzodiazepine concentration and performance in suspected impaired drivers. Journal of Clinical Forensic and Legal Medicine, 2008, 15, 483-488.	0.5	15
314	Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor Users. Drug Safety, 2008, 31, 143-158.	1.4	35
315	Influence of Chemical Structure on Hypersensitivity Reactions Induced by Antiepileptic Drugs. Drug Safety, 2008, 31, 695-702.	1.4	42
316	Drug-Related Nephrotoxic and Ototoxic Reactions. Drug Safety, 2008, 31, 877-884.	1.4	19
317	Appropriateness of Prescribing among Elderly Patients in a Dutch Residential Home. Drugs and Aging, 2008, 25, 947-954.	1.3	76
318	Drug treatment-related factors of inadequate seizure control. Epilepsy and Behavior, 2008, 13, 545-548.	0.9	5
319	Perifollicular Xanthomatosis as the Hallmark of Axillary Fox-Fordyce Disease. Archives of Dermatology, 2008, 144, 1020-4.	1.7	423
320	Characteristics and Reasons Associated with Nonacceptance of Selective Serotonin-Reuptake Inhibitor Treatment. Annals of Pharmacotherapy, 2008, 42, 218-225.	0.9	38
321	The Relation Between the Use of Psychoactive Substances and the Severity of the Injury in a Group of Crash-Involved Drivers Admitted to a Regional Trauma Center. Traffic Injury Prevention, 2008, 9, 105-108.	0.6	15
322	Association Between Hospitalization and Discontinuity of Medication Therapy Used in the Community Setting in the Netherlands. Annals of Pharmacotherapy, 2008, 42, 933-939.	0.9	22
323	Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. JAMA - Journal of the American Medical Association, 2008, 300, 1887.	3.8	218
324	The Association between Concomitant Use of Serotonergic Antidepressants and Lithium-Induced Polyuria. A Multicenter Medical Chart Review Study. Pharmacopsychiatry, 2008, 41, 129-133.	1.7	7

#	Article	IF	CITATIONS
325	Visualizing Pharmacological Activities of Antidepressants: A Novel Approach. The Open Pharmacology Journal, 2008, 2, 54-62.	0.4	28
326	The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics Journal, 2007, 7, 318-324.	0.9	46
327	The Association between Exposure to COX-2 Inhibitors and Schizophrenia Deterioration. A Nested Case-Control Study. Pharmacopsychiatry, 2007, 40, 111-115.	1.7	13
328	Aggression of Psychiatric Patients Associated with the Use of As-needed Medication. Pharmacopsychiatry, 2007, 40, 25-29.	1.7	15
329	Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clinical Chemistry and Laboratory Medicine, 2007, 45, 13-9.	1.4	110
330	Compliance with National Guidelines for the Management of Drug–Drug Interactions in Dutch Community Pharmacies. Annals of Pharmacotherapy, 2007, 41, 2024-2031.	0.9	17
331	The Association Between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 338-343.	0.7	76
332	No increased incidence of diabetes in antidepressant users. International Clinical Psychopharmacology, 2007, 22, 382-386.	0.9	49
333	Depressive Symptoms in Subjects With Diagnosed and Undiagnosed Type 2 Diabetes. Psychosomatic Medicine, 2007, 69, 300-305.	1.3	106
334	Lithium use and the risk of fractures. Bone, 2007, 40, 1252-1258.	1.4	59
335	Signal Detection. Drug Safety, 2007, 30, 607-609.	1.4	16
336	Prevalence of Patients Using Drugs Metabolized by Cytochrome P450 2D6 in Different Populations: a Cross-Sectional Study. Annals of Pharmacotherapy, 2007, 41, 408-413.	0.9	31
337	Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiology and Drug Safety, 2007, 16, 189-196.	0.9	15
338	VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement. Clinical Pharmacology and Therapeutics, 2007, 81, 185-193.	2.3	93
339	The impact of environmental temperature on lithium serum levels. Bipolar Disorders, 2007, 9, 603-608.	1.1	18
340	Valproic Acid?induced Hair-texture Changes in a White Woman. Epilepsia, 2007, 48, 400-401.	2.6	22
341	Indications for antidepressant drug prescribing in general practice in the Netherlands. Journal of Affective Disorders, 2007, 98, 109-115.	2.0	141
342	Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration. European Journal of Pharmacology, 2007, 566, 50-57.	1.7	13

#	Article	IF	CITATIONS
343	Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics, 2007, 8, 159-176.	0.6	21
344	Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. European Journal of Clinical Pharmacology, 2007, 63, 181-187.	0.8	11
345	Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system. European Journal of Clinical Pharmacology, 2007, 63, 1193-1199.	0.8	43
346	Quality improvement of oral medication administration in patients with enteral feeding tubes. Quality and Safety in Health Care, 2006, 15, 44-47.	2.5	76
347	Drug-Induced Thrombocytopenia. Drug Safety, 2006, 29, 713-721.	1.4	29
348	Clinical Risk Management in Dutch Community Pharmacies. Drug Safety, 2006, 29, 723-732.	1.4	40
349	Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Critical Care, 2006, 10, R93.	2.5	54
350	Difference in Risks of Allergic Reaction to Sulfonamide Drugs Based on Chemical Structure. Annals of Pharmacotherapy, 2006, 40, 1040-1046.	0.9	36
351	The Association Between Cytochrome P450-2D6 Genotype and Prescription of Antiparkinsonian Drugs in Hospitalized Psychiatric Patients Using Antipsychotics. Journal of Clinical Psychopharmacology, 2006, 26, 212-215.	0.7	4
352	The impact of Cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiology and Drug Safety, 2006, 15, 107-114.	0.9	27
353	Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiology and Drug Safety, 2006, 15, 338-343.	0.9	28
354	Right-to-Left Shunt and Migraine: The Strength of the Relationship. Cephalalgia, 2006, 26, 208-213.	1.8	32
355	Risk of Aplastic Anemia in Patients Using Antiepileptic Drugs. Epilepsia, 2006, 47, 1232-1236.	2.6	75
356	RESPONSE LETTERS TO DRS. WANG, AND SEITZ AND GILL. Journal of the American Geriatrics Society, 2006, 54, 861-863.	1.3	7
357	VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clinical Pharmacology and Therapeutics, 2006, 80, 13-22.	2.3	127
358	Identification of Potential Drug-related Problems in the Elderly: The Role of the Community Pharmacist. International Journal of Clinical Pharmacy, 2006, 28, 33-38.	1.4	69
359	Prevalence and patterns of antidepressant drug use during pregnancy. European Journal of Clinical Pharmacology, 2006, 62, 863-870.	0.8	162
360	QTc Prolongation and Torsades de Pointes in an Elderly Woman Taking Fluoxetine. American Journal of Psychiatry, 2006, 163, 325-325.	4.0	32

#	Article	IF	CITATIONS
361	Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology, 2006, 67, 1128-1134.	1.5	104
362	Use of antiepileptic drugs and risk of fractures: Case-control study among patients with epilepsy. Neurology, 2006, 66, 1318-1324.	1.5	197
363	Comparison of Urine and Oral Fluid as Matrices for Screening of Thirty-Three Benzodiazepines and Benzodiazepine-like Substances using Immunoassay and LC-MS(-MS). Journal of Analytical Toxicology, 2006, 30, 478-485.	1.7	42
364	Represcription After Adverse Drug Reaction in the Elderly: A Descriptive Study. Archives of Internal Medicine, 2006, 166, 1666.	4.3	60
365	Early Identification of Long-Term Poor Adherence in Ambulatory Patients. Annals of Pharmacotherapy, 2006, 40, 2277-2278.	0.9	2
366	Haloperidol Dose When Used as Active Comparator in Randomized Controlled Trials With Atypical Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2006, 67, 897-903.	1.1	43
367	Pharmacotherapy for the Treatment of Aggressive Behavior in General Adult Psychiatry. Journal of Clinical Psychiatry, 2006, 67, 1013-1024.	1.1	81
368	The Pharmacological Management of Aggression. , 2006, , 173-190.		0
369	The Association Between Cytochrome P450 2D6 Genotype and Prescription Patterns of Antipsychotic and Antidepressant Drugs in Hospitalized Psychiatric Patients. Journal of Clinical Psychopharmacology, 2005, 25, 188-191.	0.7	30
370	Impaired Glucose Homeostasis After Imipramine Intake in a Diabetic Patient. Journal of Clinical Psychopharmacology, 2005, 25, 621-623.	0.7	7
371	Effectiveness of lamotrigine in clinical practice: Results of a retrospective population-based study. Epilepsy Research, 2005, 65, 93-100.	0.8	17
372	Drug use and the severity of a traffic accident. Accident Analysis and Prevention, 2005, 37, 427-433.	3.0	55
373	Cost-effectiveness of add-on lamotrigine therapy in clinical practice. Epilepsy Research, 2005, 67, 143-151.	0.8	10
374	Effect of Low-Intensity Acenocoumarol on Frequency and Severity of Migraine Attacks. Headache, 2005, 45, 137-143.	1.8	17
375	Haloperidol Prophylaxis for Elderly Hipâ€Surgery Patients at Risk for Delirium: A Randomized Placeboâ€Controlled Study. Journal of the American Geriatrics Society, 2005, 53, 1658-1666.	1.3	604
376	Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice. Bipolar Disorders, 2005, 7, 274-280.	1.1	30
377	Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a followâ€up study. British Journal of Clinical Pharmacology, 2005, 60, 641-647.	1.1	57
378	Incidence of Fractures among Epilepsy Patients: A Population-based Retrospective Cohort Study in the General Practice Research Database. Epilepsia, 2005, 46, 304-310.	2.6	192

#	Article	IF	CITATIONS
379	The impact of hospitalisation on the initiation and long-term use of benzodiazepines. European Journal of Clinical Pharmacology, 2005, 61, 291-295.	0.8	20
380	Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. European Journal of Clinical Pharmacology, 2005, 61, 303-307.	0.8	56
381	Methylphenidate: Use in Daily Practice. International Journal of Clinical Pharmacy, 2005, 27, 197-201.	1.4	10
382	Causal or casual?. Pharmacoepidemiology and Drug Safety, 2005, 14, 365-366.	0.9	4
383	Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not. Pharmacoepidemiology and Drug Safety, 2005, 14, 107-112.	0.9	10
384	Reasons for Switching between Antipsychotics in Daily Clinical Practice. Pharmacopsychiatry, 2005, 38, 122-124.	1.7	35
385	Disease and Intolerability Documentation in Electronic Patient Records. Annals of Pharmacotherapy, 2005, 39, 1640-1646.	0.9	10
386	Risk of hip/femur fractures in patients using antipsychotics. Bone, 2005, 37, 864-870.	1.4	69
387	Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation. Drugs and Aging, 2005, 22, 353-360.	1.3	38
388	Need for medicine-based evidence in pharmacotherapy. British Journal of Psychiatry, 2004, 184, 452-452.	1.7	13
389	Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart, 2004, 90, 859-865.	1.2	381
390	Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 131-138.	0.7	12
391	Evaluation of the clinical value of pharmacists' modifications of prescription errors. British Journal of Clinical Pharmacology, 2004, 58, 503-511.	1.1	67
392	A Thromboembolic Predisposition and the Effect of Anticoagulants on Migraine. Headache, 2004, 44, 399-402.	1.8	15
393	Closing the loop of the medication use process using electronic medication administration registration. International Journal of Clinical Pharmacy, 2004, 26, 185-190.	1.4	15
394	Discontinuities in drug use upon hospital discharge. International Journal of Clinical Pharmacy, 2004, 26, 268-270.	1.4	9
395	Incidence and determinants of long-term use of antidepressants. European Journal of Clinical Pharmacology, 2004, 60, 57-61.	0.8	90
396	Increased psychotropic drug consumption by children in the Netherlands during 1995?2001 is caused by increased use of methylphenidate by boys. European Journal of Clinical Pharmacology, 2004, 60, 377-9.	0.8	40

#	Article	IF	Citations
397	Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice. European Journal of Clinical Pharmacology, 2004, 60, 751-758.	0.8	14
398	The reporting odds ratio versus the proportional reporting ratio:â€~deuce'. Pharmacoepidemiology and Drug Safety, 2004, 13, 525-526.	0.9	61
399	Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy-a pilot study. Pharmacoepidemiology and Drug Safety, 2004, 13, 41-47.	0.9	21
400	Psychoactive substance use and the risk of motor vehicle accidents. Accident Analysis and Prevention, 2004, 36, 631-636.	3.0	269
401	Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood by liquid chromatography?(tandem) mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 811, 13-20.	1.2	41
402	The Risk of Cancer in Users of Statins. Journal of Clinical Oncology, 2004, 22, 2388-2394.	0.8	475
403	Less medication switching after initial start with atypical antipsychotics. European Neuropsychopharmacology, 2004, 14, 1-5.	0.3	8
404	Failure to Continue Lipid-Lowering Drug Use Following the Withdrawal of Cerivastatin. Drug Safety, 2004, 27, 63-70.	1.4	8
405	Drug-Induced Immune Thrombocytopenia. Drug Safety, 2004, 27, 1243-1252.	1.4	114
406	Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Archives of Internal Medicine, 2004, 164, 2367.	4.3	219
407	Determinants for successful smoking cessation with bupropion in daily practice. International Journal of Clinical Pharmacy, 2003, 25, 207-211.	1.4	2
408	Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies. International Journal of Clinical Pharmacy, 2003, 25, 280-287.	1.4	21
409	Diffusion of new medicines into hospital practice. European Journal of Clinical Pharmacology, 2003, 59, 495-496.	0.8	0
410	Single Use of Sumatriptan: A Patient Interview Study. Headache, 2003, 43, 109-116.	1.8	23
411	Migraine Prophylactic Medication Usage Patterns in the Netherlands. Cephalalgia, 2003, 23, 293-301.	1.8	34
412	Use of alpha-blockers and the risk of hip/femur fractures. Journal of Internal Medicine, 2003, 254, 548-554.	2.7	51
413	Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. Journal of Clinical Epidemiology, 2003, 56, 530-535.	2.4	77
414	Incidence and determinants of antidepressant drug use in migraine patients. International Clinical Psychopharmacology, 2003, 18, 331-339.	0.9	3

#	Article	IF	CITATIONS
415	Relationship of Serotonergic Antidepressants and Need for Blood Transfusion in Orthopedic Surgical Patients. Archives of Internal Medicine, 2003, 163, 2354.	4.3	141
416	Risk factors for the development of lithium-induced polyuria. British Journal of Psychiatry, 2003, 182, 319-323.	1.7	37
417	Channelling new antidepressants to problem patients may be factor in fatal toxicity. BMJ: British Medical Journal, 2003, 326, 600a-600.	2.4	5
418	Patterns of lipid lowering drug use after the withdrawal of cerivastatin. British Journal of Clinical Pharmacology, 2002, 54, 559-560.	1.1	0
419	Frequency and determinants of drug administration errors in the intensive care unit*. Critical Care Medicine, 2002, 30, 846-850.	0.4	168
420	Use of Measures of Disproportionality in Pharmacovigilance. Drug Safety, 2002, 25, 453-458.	1.4	138
421	Signal Selection and Follow-Up in Pharmacovigilance. Drug Safety, 2002, 25, 459-465.	1.4	82
422	Different Risks for NSAID-Induced Anaphylaxis. Annals of Pharmacotherapy, 2002, 36, 24-29.	0.9	50
423	Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. European Journal of Clinical Pharmacology, 2002, 58, 143-148.	0.8	54
424	Incidence and determinants of migraine prophylactic medication in the Netherlands. European Journal of Clinical Pharmacology, 2002, 58, 149-155.	0.8	14
425	Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. Journal of Clinical Pharmacy and Therapeutics, 2002, 27, 107-110.	0.7	32
426	In Reply Journal of the American Geriatrics Society, 2002, 50, 399-400.	1.3	0
427	Association between antidepressant drug use and hyponatraemia: a case-control study. British Journal of Clinical Pharmacology, 2002, 53, 363-369.	1.1	93
428	Non-sedating antihistamine drugs and cardiac arrhythmias - biased risk estimates from spontaneous reporting systems?. British Journal of Clinical Pharmacology, 2002, 53, 370-374.	1.1	44
429	Limited adherence to safety instructions in drug leaflets. British Journal of Clinical Pharmacology, 2002, 54, 678-679.	1.1	5
430	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11, 3-10.	0.9	822
431	Fate of abstracts presented at five International Conferences on Pharmacoepidemiology (ICPE): 1995-1999. Pharmacoepidemiology and Drug Safety, 2002, 11, 105-111.	0.9	24
432	Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiology and Drug Safety, 2002, 11, 271-279.	0.9	93

#	Article	IF	CITATIONS
433	Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. International Journal of Impotence Research, 2002, 14, 259-265.	1.0	75
434	Is Sexual Dysfunctioning a Reason for Discontinuation in Users of Selective Serotonin Reuptake Inhibitors?. Journal of Clinical Psychopharmacology, 2002, 22, 96-98.	0.7	6
435	Reduction in the Intensity of Abortive Migraine Drug Use During Coumarin Therapy. Headache, 2001, 41, 768-773.	1.8	22
436	Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. Journal of the American Geriatrics Society, 2001, 49, 234-235.	1.3	15
437	The Dutch cohort of sildenafil users: baseline characteristics. BJU International, 2001, 87, 648-653.	1.3	5
438	Patterns of Ergotamine and Sumatriptan Use in the Netherlands from 1991 to 1997. Cephalalgia, 2001, 21, 596-603.	1.8	11
439	Nature, frequency and determinants of prescription modifications in Dutch community pharmacies. British Journal of Clinical Pharmacology, 2001, 52, 85-91.	1.1	58
440	Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. British Journal of Clinical Pharmacology, 2001, 52, 579-586.	1.1	54
441	Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?. Pharmacoepidemiology and Drug Safety, 2001, 10, 135-142.	0.9	20
442	Assessment of indicators for hospital drug formulary non-adherence. European Journal of Clinical Pharmacology, 2001, 57, 677-684.	0.8	11
443	Risk factors for the development of adverse drug events in hospitalized patients. International Journal of Clinical Pharmacy, 2000, 22, 62-66.	1.4	90
444	Stabilization of oral anticoagulant therapy in hospitalized patients and characteristics associated with lack of stabilization. International Journal of Clinical Pharmacy, 2000, 22, 147-151.	1.4	4
445	Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. European Journal of Clinical Pharmacology, 2000, 56, 319-322.	0.8	5
446	Consequences of a change in reimbursement status on prescription patterns. European Journal of Clinical Pharmacology, 2000, 56, 511-512.	0.8	7
447	Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology, 2000, 56, 733-738.	0.8	105
448	Automated Extraction of 11-nor-Â9-Tetrahydrocannabinol Carboxylic Acid from Urine Samples Using the ASPEC XLÂ Solid-Phase Extraction System. Journal of Analytical Toxicology, 2000, 24, 433-437.	1.7	12
449	Selective Prescribing of Spasmolytics. Annals of Pharmacotherapy, 2000, 34, 716-720.	0.9	10
450	Drug-Related Problems in Hospitalised Patients. Drug Safety, 2000, 22, 321-333.	1.4	155

#	Article	IF	Citations
451	An ABC of Drug-Related Problems. Drug Safety, 2000, 22, 415-423.	1.4	86
452	Analysis of low concentration sufentanil citrate/bupivacaine hydrochloride admixtures, using solid phase extraction followed by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1999, 21, 845-850.	1.4	27
453	Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. British Journal of Clinical Pharmacology, 1999, 47, 689-693.	1.1	108
454	Antidepressant drug choice for first users in two regions in The Netherlands. International Journal of Clinical Pharmacy, 1999, 21, 132-136.	1.4	11
455	Para-methylthioamphetamine, a new amphetamine designer drug of abuse. International Journal of Clinical Pharmacy, 1999, 21, 47-48.	1.4	18
456	Adverse drug events in hospitalized patients. European Journal of Clinical Pharmacology, 1999, 55, 155-158.	0.8	125
457	Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. European Journal of Pediatrics, 1999, 158, 975-977.	1.3	58
458	Pharmacovigilance in Perspective. Drug Safety, 1999, 21, 429-447.	1.4	94
459	Incidence of Discontinuation of Highly Active Antiretroviral Combination Therapy (HAART) and Its Determinants. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 290-294.	0.3	82
460	Performance of Abusignâ,,¢ Drugs-of-Abuse Slide Tests with Particular Emphasis on Concentrations Near the Cutoff: Comparison with FPIA-ADx and Confirmation of Results with GC-MS. Journal of Analytical Toxicology, 1998, 22, 40-44.	1.7	15
461	Serotonin syndrome attributed to tramadol addition to paroxetine therapy. International Clinical Psychopharmacology, 1997, 12, 181.	0.9	42
462	Principles of Signal Detection in Pharmacovigilance. Drug Safety, 1997, 16, 355-365.	1.4	182
463	Causal or Casual?. Drug Safety, 1997, 17, 374-389.	1.4	201
464	Non-puerperal lactation associated with antidepressant drug use. British Journal of Clinical Pharmacology, 1997, 44, 277-281.	1.1	64
465	ADR related questions received by a telephone medicines information service and ADRs received by a spontaneous ADR reporting system: a comparison regarding patients and drugs., 1997, 6, 269-276.		8
466	Channeling of Three Newly Introduced Antidepressants to Patients Not Responding Satisfactorily to Previous Treatment. Journal of Clinical Psychopharmacology, 1997, 17, 149-155.	0.7	31
467	Characteristics of Topics in Pharmacovigilance in The Netherlandsâ€. Clinical Drug Investigation, 1996, 12, 207-219.	1.1	14
468	Reduction of Migrainous Headaches During the Use of Acenocoumarol. Headache, 1996, 36, 48-48.	1.8	18

ANTOINE C G EGBERTS

#	Article	IF	CITATIONS
469	Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ: British Medical Journal, 1996, 313, 530-531.	2.4	92
470	Application of radioreceptor assays for systematic toxicological analysis—1. Procedures for radioreceptor assays for antihistaminics, anticholinergics and benzodiazepines. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 53-58.	1.4	13
471	Application of radioreceptor assays for systematic toxicological analysis — 2. Theoretical considerations and evaluation. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 59-63.	1.4	8
472	Prophylaxis for Venous Thromboembolism in Hip Fracture Surgery. Pharmacoeconomics, 1994, 5, 48-55.	1.7	15
473	Performance of a trigger tool for detecting adverse drug reactions in patients with polypharmacy acutely admitted to the geriatric ward. European Geriatric Medicine, 0, , .	1.2	1